RxDoctor Payments Data

Nichole Clark

Family · Clinton, ARNPI 1548464936

Payments from drug & device makers

$318in general payments, 2019–2025

Across 18 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$78
  • Currax Pharmaceuticals LLC$50
  • E.r. Squibb & Sons, L.L.C.$45
  • GSK$30
  • Abbott$24
  • Boehringer Ingelheim$22
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$26884%
  • Education$5016%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$318 in reported general payments places this provider in the 45th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$2,792
Medicare patients
173
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide224$239,432
JardianceEmpagliflozin253$185,732
EliquisApixaban231$168,541
Trelegy ElliptaFluticasone/Umeclidin/Vilanter177$128,264
MounjaroTirzepatide98$121,550
Breztri AerosphereBudesonide/Glycopyr/Formoterol80$56,764
XifaxanRifaximin26$56,761
LinzessLinaclotide84$55,703
TrulicityDulaglutide34$41,966
JanuviaSitagliptin Phosphate41$35,481
MyrbetriqMirabegron128$34,679
XareltoRivaroxaban51$31,251
Tresiba Flextouch U-200Insulin Degludec26$30,173
Spiriva HandihalerTiotropium Bromide35$25,573
RybelsusSemaglutide18$24,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$17$263,684242 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Glyxambi$22$211,548292 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$30$183,080278 claims
PfizerEliquis$20$168,541231 claims
Lilly USA, LLCMounjaro, Trulicity$15$163,515132 claims
AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere, Brilinta$78$96,025144 claims
AbbVieLinzess$17$55,70384 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,103 family providers in Arkansas.

Other family in Clinton

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →